Annaloro C, Serpenti F, Saporiti G, Galassi G, Cavallaro F, Grifoni F, et al. Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. Front Immunol. 2021;11:569381.

Article  PubMed  PubMed Central  Google Scholar 

Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a Bidirectional Relationship between Cytomegalovirus Replication and acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2010;16:1309–14.

Article  PubMed  Google Scholar 

Qayed M, Khurana M, Hilinski J, Gillespie S, McCracken C, Applegate K, et al. Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2015;62:364–6.

Article  PubMed  Google Scholar 

Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135:1619–29.

Article  PubMed  PubMed Central  Google Scholar 

Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54:1290–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377:2433–44.

Article  CAS  PubMed  Google Scholar 

César T, Le MP, Klifa R, Castelle M, Fournier B, Levy R, et al. Letermovir for CMV Prophylaxis in Very High-Risk Pediatric Hematopoietic Stem Cell Transplantation Recipients for Inborn Errors of Immunity. J Clin Immunol. 2024;44:1–9.

Article  Google Scholar 

Chavaz L, Royston L, Masouridi-Levrat S, Mamez A, Giannotti F, Morin S, et al. CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients. Open Forum Infect Dis. 2023;10:ofad169.

Article  PubMed  PubMed Central  Google Scholar 

Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20:1703–11.

Article  CAS  PubMed  Google Scholar